Most Read Articles
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
08 Sep 2017
Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
06 Aug 2017
A recent study has shown the safety, efficacy and tolerance of fluoxetine for hypochondriasis. Moreover, joint treatment with both fluoxetine and cognitive behavioural therapy (CBT) confers a small incremental benefit over a single active treatment.

Pregnancy warning needed on hydroquinone-containing OTC products

14 Sep 2017

There appears to be a lack of pregnancy warning on hydroquinone-containing over-the-counter (OTC) dermatologic products, highlighting the need for improved labelling, according to a study.

Researchers obtained data from the Food and Drug Administration National Drug Code Directory and Label Repository and identified 112 OTC dermatologic products containing hydroquinone, an ingredient potentially harmful to foetus. Products were grouped into two, based on the presence or absence of pregnancy or general warning. Product characteristics including hydroquinone concentration, presence of external packaging, indication and warning statements were compared between the two groups.

Of the products studied, 21 had a pregnancy warning and three included a general warning against use. External packaging was more common in the warning-present group than in the warning-absent group (62.5 vs 29.5 percent; p=0.004).

Pregnant women deal with the challenge of choosing OTC drugs and personal care products (eg, cosmetics) that should not pose a safety threat to their foetus, researchers said. This underscores the importance of labelling OTC products for use by women of childbearing age, and the labels should communicate caution if a potentially harmful ingredient in the product should be either avoided or used in limited amounts during pregnancy.

There are a number of OTC products commonly used for conditions during pregnancy (eg, constipation, acne, dark spots and melasma), and these products may contain harmful ingredients that are potentially harmful to the foetus (eg, retinoids and hydroquinone). [J Am Acad Dermatol 2014;70:401; Coll Antropol 2008;32:139–141]

“Topical application of harmful ingredients may achieve percutaneous absorption into systemic circulation and reach foetal circulation. However, quantification of blood levels has not been performed for many topical agents to identify potential risk,” researchers noted.

Findings of the present study serve to increase awareness of OTC labelling limitations and call for action to protect pregnant women and their foetus, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
08 Sep 2017
Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
06 Aug 2017
A recent study has shown the safety, efficacy and tolerance of fluoxetine for hypochondriasis. Moreover, joint treatment with both fluoxetine and cognitive behavioural therapy (CBT) confers a small incremental benefit over a single active treatment.